{"analyses":[{"ciLowerLimit":"0.330","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.678","estimateComment":"The hazard ratio was estimated using a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Only primary and key secondary endpoints were formally tested; this endpoint was not formally tested.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.473","statisticalMethod":"stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.6","upperLimit":"94.6","value":"91.5"},{"groupId":"OG001","lowerLimit":"70.9","upperLimit":"83.2","value":"77.8"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.4","upperLimit":"82.4","value":"76.3"},{"groupId":"OG001","lowerLimit":"50.3","upperLimit":"66.9","value":"59.1"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.4","upperLimit":"72.2","value":"63.7"},{"groupId":"OG001","lowerLimit":"33.1","upperLimit":"52.4","value":"42.9"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.4","upperLimit":"57.1","value":"39.5"},{"groupId":"OG001","lowerLimit":"20.5","upperLimit":"46.6","value":"33.3"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"199"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake \\> mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately \\> liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by \\>50% in length beyond normal; (4) no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL: Placebo + Rituximab + Lenalidomide"},{"description":"Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG002","title":"MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG003","title":"MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"NUMBER","populationDescription":"FL Full Analysis Set. Only those participants who achieved an objective response (CR or PR) were analyzed. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percent probability"}